

1 WHAT IS CLAIMED IS:

2 1. A medicinal preparation containing phenylethanoid glycosides
3 extracted from *Cistance tubulosa (Schenk.) Wight*, said preparation
4 comprising 10-70% of echinacoside by weight of said preparation, and
5 1-40% of acteoside by weight of said preparation.

6

7 2. The preparation as defined in claim 1 comprising 25-70% of
8 echinacoside by weight of said preparation, and 5-40% of acteoside by
9 weight of said preparation.

10

11 3. The preparation as defined in claim 1 which is extracted from
12 fleshy stems of *Cistance tubulosa (Schenk.) Wight*.

13

14 4. The preparation as defined in claim 1 further comprising
15 2'-acetylacteoside; campneoside I; campneoside II; cistantubuloside A, B₁,
16 B₂, C₁, C₂; crenatoside; decaffeoylacteoside; isoacteoside; rhodioloside;
17 syringalide A; 3'- α -L-rhamnopyranoside, and tubuloside A, each being
18 contained in an amount less than 5% by weight of said preparation.

19

20 5. A process for making a medicinal preparation containing
21 phenylethanoid glycosides, said process comprising the following steps of:
22 a) extracting subterranean portions of *Cistanche tubulosa*
23 (Schenk.) Wight with a first polar solvent;
24 b) introducing the resulting extract from step a) into a column
25 which is packed with hydrophobic macro-porous polymeric beads, thereby
26 enabling phenylethanoid glycosides to be adsorbed on the polymeric
27 beads;

1 c) eluting the column by use of a second polar solvent serving as
2 a mobile phase, so that relatively less strongly adsorbed compounds are
3 eluted from the column with most of phenylethanoid glycosides still being
4 adsorbed on the polymeric beads; and

5 d) eluting the column by use of a third polar solvent so as to
6 obtain an eluate which contains phenylethanoid glycosides, wherein the
7 third polar solvent is lower in polarity than the second polar solvent.

8

9 6. The process as defined in claim 5, wherein the subterranean
10 portions of *Cistanche tubulosa (Schenk.) Wight* in step a) are fleshy
11 stems.

12

13 7. The process as defined in claim 5, wherein said extracting in
14 step a) comprises mixing the subterranean portions of *Cistanche tubulosa*
15 (Schenk.) Wight with the first polar solvent, decocting the resulting mixture
16 for 0.5-10 hours, and filtering the decocted mixture to obtain a liquid
17 extract or concentrating the liquid in vacuo to obtain an extract in the
18 concentrated form.

19

20 8. The process as defined in claim 7, wherein the first polar
21 solvent is water, or a mixture of water and ethanol.

22

23 9. The process as defined in claim 5, wherein the polymeric
24 beads in step b) are cross-linked polyaromatics.

25

1 10. The process as defined in claim 9, wherein the polymeric
2 beads are formed of cross-linked polystyrene or cross-linked copolymer of
3 styrene and divinyl benzene.

4

5 11. The process as defined in claim 5, wherein the second polar
6 solvent is water; wherein the third polar solvent is methanol, ethanol, a
7 mixture of water and methanol, or a mixture of water and ethanol.

8

9 12. The process as defined in claim 11, wherein the third polar
10 solvent is the mixture of water and ethanol.

11

12 13. The process as defined in claim 5 further comprising
13 removing a solvent that is contained in the eluate from step d), thereby
14 resulting in production of a dry preparation.

15

16 14. A medicinal composition for use in the prevention of senile
17 dementia, said medicinal composition comprising a therapeutically
18 effective amount of the preparation as claimed in any one of claims 1 to 4
19 as an active ingredient, in admixture with a pharmaceutically acceptable
20 carrier or diluent for the active ingredient.

21

22 15. A medicinal composition for use in the inhibition of
23 aggregation of blood platelets, said medicinal composition comprising a
24 therapeutically effective amount of the preparation as claimed in any one
25 of claims 1 to 4 as an active ingredient, in admixture with a
26 pharmaceutically acceptable carrier or diluent for the active ingredient.

27

1 16. A method of treating and preventing an individual suffering
2 senile dementia comprising administering to the individual a
3 therapeutically effective amount of the preparation as claimed in claim 1.

4

5 17. A method of inhibiting blood platelets aggregation in an
6 individual comprising administering to the individual a therapeutically
7 effective amount of the preparation as claimed in claim 1.

8

9 18. The method as defined in claim 14, wherein the preparation
10 comprises 25-70% of echinacoside by weight of said preparation, and
11 5-40% of acteoside by weight of said preparation.

12

13 19. The method as defined in claim 14, wherein the preparation
14 is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

15

16 20. The method as defined in claim 15, wherein the preparation
17 comprises 25-70% of echinacoside by weight of said preparation, and
18 5-40% of acteoside by weight of said preparation.

19

20 21. The method as defined in claim 15, wherein the preparation
21 is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

22

23 22. The method as defined in claim 16, wherein the preparation
24 comprises 25-70% of echinacoside by weight of said preparation, and
25 5-40% of acteoside by weight of said preparation.

26

1 23. The method as defined in claim 16, wherein the preparation
2 is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

3

4 24. The method as defined in claim 17, wherein the preparation
5 comprises 25-70% of echinacoside by weight of said preparation, and
6 5-40% of acteoside by weight of said preparation.

7

8 25. The method as defined in claim 17, wherein the preparation
9 is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

10